Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05824585 · ClinicalTrials.gov registry record · Phase 1

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Dizal Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
230
Enrollment target
5
Study locations

NCT05824585 is a Phase 1 study of Lymphoma, Non-Hodgkin that is actively recruiting participants, run by Dizal Pharmaceuticals. The registered enrollment target is 230 participants, below the 390-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (41% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05824585, a Phase 1 study of Lymphoma, Non-Hodgkin, is actively recruiting participants, sponsored by Dizal Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
230 participants
Enrollment target
5
Study locations

Study Summary

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.

Conditions Studied

Lymphoma, Non-Hodgkin

Interventions

  • DRUG DZD8586

Study Locations (5)

Victoria

  • Research site - Ballarat
  • Research site - Melbourne

New York

  • Research site - New York

New South Wales

  • Research site - Albury

Western Australia

  • Research site - Perth

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2023-05-15
Est. Completion 2027-10-30
Phase Phase 1

Sponsor

Dizal Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05824585

The ClinicalTrials.gov registry entry for NCT05824585 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 390-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (41% lower). The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which DZD8586 is the first listed.

NCT05824585 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Victoria, New York, New South Wales.

Frequently Asked Questions

What is clinical trial NCT05824585 about?

NCT05824585 is a clinical study titled "DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and ...

What is the current status of trial NCT05824585?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2023-05-15. Estimated completion is 2027-10-30.

What conditions does trial NCT05824585 study?

This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin.

What interventions are being tested in trial NCT05824585?

The interventions under investigation include: DZD8586 (DRUG).

Who is sponsoring clinical trial NCT05824585?

This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05824585 being conducted?

This trial has 5 study locations across New York, New South Wales, Victoria, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, Non-Hodgkin

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma, Non-Hodgkin

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.